Clinical Trial Update: Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA [Phase 3]

View source ↗

Summary

Phase 3 multicenter randomized trial evaluating intravenous ferric carboxymaltose (FCM) in pediatric iron deficiency anemia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iron Deficiency Anemia

Drugs mentioned

• intravenous ferric carboxymaltose (ferric carboxymaltose)

Snippet

Sponsor: American Regent, Inc. | Conditions: Iron Deficiency Anemia | Phase 3 | Status: COMPLETED | Results posted: 2022-06-22